Form 4: OnKure Therapeutics CFO Acquires Stock Options

OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, was granted 65,000 stock options on January 27, 2025.

Summary

• Jason A. Leverone, the Chief Financial Officer of OnKure Therapeutics, Inc., was granted 65,000 employee stock options on January 27, 2025.
• The options have an exercise price of $5.19 per share.
• The options vest monthly, with 1/48th of the shares vesting each month starting February 27, 2025, contingent on continued service.
• The options expire on January 26, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative or unexpected events.

Positives

• The granting of stock options to the CFO aligns his interests with the company's long-term success.
• The vesting schedule encourages continued service and commitment from the CFO.

Future Outlook

The vesting of the stock options is contingent on the CFO's continued service with the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often with vesting schedules tied to continued employment.
• The exercise price of $5.19 is specific to OnKure's valuation and is not directly comparable to other companies without further context.
• The 10-year expiration period is typical for stock options.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates

Keywords

stock options, insider trading, executive compensation, OnKure Therapeutics, OKUR, CFO, Jason A. Leverone, vesting